BRAF and neoplasm: Patients who received at least 6 months of BRAF inhibitor therapy had superior ORR to subsequent anti-PD-1 therapy compared with those with more rapid progression (< 6 months) on BRAFi (34% versus 15%, p = 0.04), suggesting that this negative impact was a reflection of baseline tumor biology rather than an impact of the BRAFi therapy on the tumor immune microenvironment.